Liquid Biopsy Test

What is Liquid Biopsy?

Liquid biopsy is a minimally invasive diagnostic approach that isolates and analyses circulating tumor genomic markers from the blood to provide insights on Treatment efficacy, Early detection, Quantification of Disease Burden, MRD status, and Disease Surveillance. It is an alternative approach to invasive tissue biopsy-based genomic testing.

Liquid biopsies could provide a potential revolution in the field of cancer diagnosis and treatment.The analytes which are released by tumors in bodily fluids and analyzed as biomarker by liquid biopsy for the diagnosis of cancer are circulating tumour cells (CTCs),circulating nucleic acids (circulating tumour DNA (ctDNA),the tumour-derived fraction of cell-free DNA (cfDNA) in the plasma and cell-free RNAs (mRNAs, long non-coding RNAs and microRNAs), extracellular vesicles, tumour-educated platelets, proteins and metabolites.

When should a liquid biopsy be ordered?

Liquid biopsy can be suggested in different stages of the cancer management journey but majorly it is ordered in two different scenarios. When there are limited or no options to extract tumor tissue through tissue biopsy. The second scenario is to detect the presence of MRD or Minimal Residual Disease. Other indications where Liquid Biopsy suggestions are given include Baseline molecular profiling testing, Early detection of the disease, Quantification of disease burden to name a few.

Who needs to get tested?

Cancer patients who fit in one of the following categories are eligible for a liquid biopsy test.
  1. For patients where invasive tissue biopsy is not an option.
  2. The tissue biopsy material is old, damaged, or not properly fixed in FFPE.
  3. Where the tissue is limited or no tissue is present for further analysis.
Disclaimer: Though Liquid biopsy is a minimally invasive, advantageous investigational test over tissue
biopsy, it is not ideal for diagnostic purposes and does not replace conventional biopsy which is the
"Gold Standard".

When does a person need to get tested with Liquid Biopsy?

Cancer patients who fit in one of the following categories are eligible for a Liquid biopsy test:
  1. Examining the efficiency of the cancer treatment and monitoring the rate of relapse.
  2. Comprehensive analysis of the cancer resistance.
  3. Assessment of cancer patients' clinical response toward a treatment.

How Liquid Biopsy testing differs from Tissue biopsy testing?

In oncology, liquid biopsies are used for various reasons. They can be used as a screening technique for early detection by looking for specific mutations or evaluating the entire sample for mutations. They are critical in the precision therapy and monitoring of relapse in patients who are in remission. NGS approaches are utilized to detect genomic modifications of interest in each of these cases. Liquid testing also takes a considerably smaller sample and produces results much faster than tissue biopsies.

Tissue biopsies are valuable in determining the nature of tumors, including the type of malignancy, tumor gene expression, and the presence of treatment-resistant mutations. However, several factors influence this such as tumor location, amount of tissue available, and accessibility for surgical removal. In such scenarios, liquid biopsy becomes a potent alternative for the diagnosis of cancer.

Disclaimer: Though liquid biopsy is a minimally invasive, advantageous investigational test over tissue biopsy, it is not ideal for diagnostic purposes and does not replace conventional biopsy which is the "Gold Standard".

What are the future applications of liquid biopsy?

Liquid biopsy has the potential to aid in the management of cancer such as Non-Small Cell Lung Cancer (NSCLC). It has the ability to detect cancer at all stages of the disease, cancer screening, MRD detection to guide adjuvant treatment, early identification of relapse, the commencement of systemic treatment, response monitoring (targeted or immunotherapy), and resistance genotyping.
Liquid Biopsy: The How What and Why Liquid Biopsy: Cancer

What is Liquid Biopsy?

Liquid biopsy is a minimally invasive diagnostic approach that isolates and analyses circulating tumor genomic markers from the blood to provide insights on Treatment efficacy, Early detection, Quantification of Disease Burden, MRD status, and Disease Surveillance. It is an alternative approach to invasive tissue biopsy-based genomic testing.

Liquid biopsies could provide a potential revolution in the field of cancer diagnosis and treatment.The analytes which are released by tumors in bodily fluids and analyzed as biomarker by liquid biopsy for the diagnosis of cancer are circulating tumour cells (CTCs),circulating nucleic acids (circulating tumour DNA (ctDNA),the tumour-derived fraction of cell-free DNA (cfDNA) in the plasma and cell-free RNAs (mRNAs, long non-coding RNAs and microRNAs), extracellular vesicles, tumour-educated platelets, proteins and metabolites.


Liquid Biopsy: The How What and Why

When should a liquid biopsy be ordered?

Liquid biopsy can be suggested in different stages of the cancer management journey but majorly it is ordered in two different scenarios. When there are limited or no options to extract tumor tissue through tissue biopsy. The second scenario is to detect the presence of MRD or Minimal Residual Disease. Other indications where Liquid Biopsy suggestions are given include Baseline molecular profiling testing, Early detection of the disease, Quantification of disease burden to name a few.


Liquid Biopsy: Cancer

Who needs to get tested?

Cancer patients who fit in one of the following categories are eligible for a liquid biopsy test.
  1. For patients where invasive tissue biopsy is not an option.
  2. The tissue biopsy material is old, damaged, or not properly fixed in FFPE.
  3. Where the tissue is limited or no tissue is present for further analysis.
Disclaimer: Though Liquid biopsy is a minimally invasive, advantageous investigational test over tissue
biopsy, it is not ideal for diagnostic purposes and does not replace conventional biopsy which is the "Gold Standard".

When does a person need to get tested with Liquid Biopsy?

Cancer patients who fit in one of the following categories are eligible for a Liquid biopsy test:
  1. Examining the efficiency of the cancer treatment and monitoring the rate of relapse.
  2. Comprehensive analysis of the cancer resistance.
  3. Assessment of cancer patients' clinical response toward a treatment.

How Liquid Biopsy testing differs from Tissue biopsy testing?

In oncology, liquid biopsies are used for various reasons. They can be used as a screening technique for early detection by looking for specific mutations or evaluating the entire sample for mutations. They are critical in the precision therapy and monitoring of relapse in patients who are in remission. NGS approaches are utilized to detect genomic modifications of interest in each of these cases. Liquid testing also takes a considerably smaller sample and produces results much faster than tissue biopsies.

Tissue biopsies are valuable in determining the nature of tumors, including the type of malignancy, tumor gene expression, and the presence of treatment-resistant mutations. However, several factors influence this such as tumor location, amount of tissue available, and accessibility for surgical removal. In such scenarios, liquid biopsy becomes a potent alternative for the diagnosis of cancer.

Disclaimer: Though liquid biopsy is a minimally invasive, advantageous investigational test over tissue biopsy, it is not ideal for diagnostic purposes and does not replace conventional biopsy which is the "Gold Standard".

What are the future applications of liquid biopsy?

Liquid biopsy has the potential to aid in the management of cancer such as Non-Small Cell Lung Cancer (NSCLC). It has the ability to detect cancer at all stages of the disease, cancer screening, MRD detection to guide adjuvant treatment, early identification of relapse, the commencement of systemic treatment, response monitoring (targeted or immunotherapy), and resistance genotyping.

Liquid Biopsy Test Portfolio

loader